Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
March 12, 2021 07:00 ET
|
Iterum Therapeutics plc
--NDA for Oral Sulopenem has PDUFA date of July 25, 2021-- --Cash Runway into First Half of 2023— --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 12,...
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
March 05, 2021 17:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present in Upcoming Investor Conferences
February 19, 2021 17:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
February 10, 2021 18:40 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
February 09, 2021 23:58 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
February 03, 2021 23:35 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares
February 03, 2021 17:51 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
February 01, 2021 07:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
January 25, 2021 07:00 ET
|
Iterum Therapeutics plc
-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 -- DUBLIN, Ireland and CHICAGO, Jan. 25, 2021 ...
Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference
January 06, 2021 17:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...